Compare UFI & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFI | ASRT |
|---|---|---|
| Founded | 1969 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.1M | 76.0M |
| IPO Year | 1994 | 2004 |
| Metric | UFI | ASRT |
|---|---|---|
| Price | $4.27 | $22.52 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 25.6K | ★ 409.3K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $571,344,000.00 | $118,713,000.00 |
| Revenue This Year | $1.39 | N/A |
| Revenue Next Year | $12.57 | $12.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.96 | $0.60 |
| 52 Week High | $5.42 | $22.50 |
| Indicator | UFI | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 73.49 | 87.22 |
| Support Level | $3.73 | $0.70 |
| Resistance Level | $4.76 | N/A |
| Average True Range (ATR) | 0.14 | 0.18 |
| MACD | 0.06 | 0.34 |
| Stochastic Oscillator | 94.94 | 99.78 |
Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.